SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

 

(Amendment No. _)*

 

Northwest Biotherapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

66737P600

(CUSIP Number)

 

December 22, 2016

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

 

  1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

 

Woodford Investment Management Ltd

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    (a) þ

                                                                                                                                (b) ☐ 

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING 

PERSON WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

24,815,028 shares of Common Stock

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER


24,815,028 shares of Common Stock

  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

24,815,028 shares of Common Stock

  10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES       

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

16.1% (See Item 4)

  12

TYPE OF REPORTING PERSON

 

PN

       

   

  2  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

 

1

 

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

 

Neil Woodford

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP     (a)

                                                                                                                                 (b)

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

24,815,028 shares of Common Stock

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER


24,815,028 shares of Common Stock

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

24,815,028 shares of Common Stock

  10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES       

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

16.1% (See Item 4)

12

TYPE OF REPORTING PERSON

 

IN

       

 

  3  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

 

Item 1(a). Name of Issuer:
   
  Northwest Biotherapeutics, Inc. (the "Issuer")
   
Item 1(b). Address of Issuer's Principal Executive Offices:
   
  4800 Montgomery Lane, Suite 800
  Bethesda, MD 20814
   
Items 2(a),  
(b) and (c). Name of Persons Filing , Address of Principal Business Office and  Citizenship:
   
  This Schedule 13G (this “Schedule 13G”) is being filed jointly by Woodford Investment Management Ltd (the “Reporting Person”) and Neil Woodford, the Head of Investment for the Reporting Person. The joint filing agreement of the Reporting Person and Mr. Woodford is attached as Exhibit 1 to this Schedule 13G. The filers of this statement are collectively referred to herein as the “Group.”
   
  The principal business office of the Reporting Person and Mr. Woodford is 9400 Garsington Road, Oxford OX4 2HN, United Kingdom. For citizenship, see Item 4 of the cover page.    
   
Item 2(d). Title of Class of Securities:
   
  Common Stock, par value $0.001 per share (the "Common Stock")
   
Item 2(e). CUSIP Number:
   
  66737P600

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐ 78c).

 

  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

  4  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

 

  (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

 

  (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4. Ownership.

 

  (a) Amount beneficially owned :

 

The members of the Group may be deemed to have beneficial ownership of 24,815,028 shares of Common Stock. Mr. Woodford, who by virtue of acting as Head of Investments for the Reporting Person may be deemed to share beneficial ownership of the Common Stock with the Reporting Person, expressly disclaims beneficial ownership of the Common Stock beneficially owned by the Reporting Person, except to the extent of any pecuniary interest therein.

 

  (b) Percent of class :

 

Based on 154,523,139 shares of Common Stock of the Issuer outstanding as of as of December 22, 2016, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on December 28, 2016, the members of the Group hold approximately 16.1% of the issued and outstanding Common Stock of the Issuer.

 

  (c) Number of shares to which such person has :

 

(i) Sole power to vote or direct the vote: 0
     
(ii) Shared power to vote or direct the vote: 24,815,028 shares of Common Stock
     
(iii) Sole power to dispose or to direct the disposition of: 0
     
(iv) Shared power to dispose of or direct the disposition of: 24,815,028 shares of Common Stock

 

  5  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

 

Item 5. Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of a Group.

 

Not applicable.

 

Item 10. Certification.

 

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

  6  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated: January 10, 2017

 

  WOODFORD INVESTMENT MANAGEMENT LTD
       
  By: /s/ Simon Osborne
    Name: Simon Osborne
    Title:    Head of Compliance and Authorized Signatory
       
  /s/ Neil Woodford
  Neil Woodford

   

This Schedule 13G is being jointly filed by Woodford Investment Management Ltd (“WIM”) and Neil Woodford. WIM is an investment manager, authorized and regulated by the Financial Conduct Authority, in the business of investment management. Mr. Woodford serves as the Head of Investment for the Reporting Person. Mr. Woodford, as a controlling person of WIM, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended, of the securities beneficially owned by WIM. Securities reported on this Schedule 13G as being beneficially owned by WIM were purchased on behalf of its clients.

Pursuant to Rule 13d-4, Mr. Woodford declares that the filing of this Schedule 13G shall not be deemed an admission by him that he is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this Schedule 13G.

 

  7  

 

 

SCHEDULE 13G

 

CUSIP NO. 66737P600

EXHIBIT 1

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of the Issuer and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

  

Dated: January 10, 2017

 

  WOODFORD INVESTMENT MANAGEMENT LTD
       
  By: /s/ Simon Osborne
    Name: Simon Osborne
    Title:    Head of Compliance and Authorized Signatory
       
  /s/ Neil Woodford
  Neil Woodford

 

 

 

 

 

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.